Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
NCT00699179
·
clinicaltrials.gov ↗
COMPLETED
Status
2308
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Interventions
DRUG:
biphasic insulin aspart 30
Sponsor
Novo Nordisk A/S